The growing need for bone marrow donors
Close to 5,000 people in the U.S. undergo a bone marrow transplant annually. Also known as a stem cell transplant, this procedure replaces damaged or diseased bone marrow with healthy cells. The process involves wiping out the body's bone marrow and immune system with chemotherapy and sometimes radiation. Then healthy donor cells are infused intravenously [...]
The role of bridging therapy with intensive chemotherapy and/or hypomethylating agents followed by hematopoietic stem cell transplantation (HSCT) has been suggested, but there is some controversy regarding the influence of treatment response on transplant outcomes1. Considering this context, here we have investigated the influence of treatment prior to HSCT in patients with MDS.
In conclusion, taller body height at the entry to adulthood, supposed to be a marker of early-life environment, is associated with lower risk of dementia diagnosis later in life. The association persisted when adjusted for educational level and intelligence test scores in young adulthood, suggesting that height is not just acting as an indicator of cognitive reserve. A Comparison of Biological Age Measurement Approaches https://www.fightaging.org/archives/2020/02/a-comparison-of-biological-age-measurement-approaches/ Researchers here assess the performance of a range of approaches to measuring biological...
Stem cell populations become damaged and dysfunctional with age. Some of this is issues with the stem cells themselves, and some of this results from problem with the signaling environment and function of the stem cell niche. Which of these factors is more important likely varies by stem cell population. Among the best studied of stem cell types, the evidence suggests that muscle stem cells remain capable in old age, but become ever more quiescent, while hematopoietic stem cells become damaged and dysfunctional, unable to perform. Hematopoietic stem cells reside in the bone marrow and are responsible for generating blood a...
This is the latest in a series of yearly posts in which I suggest areas of development for biotech startups I'd like to see actively developed as a part of the longevity industry in the near future. Today, this year, is a good time to be starting a company focused on the production of a novel therapeutic approach to intervening in the aging process. There is a great deal of funding for seed stage investment, and many compelling projects lacking champions, yet to be carried forward from academia into preclinical development. Numerous scientific and industry crossover conferences are now held every year, at which it is possi...
Most patients suffering from classical Hodgkin's lymphoma (cHL) can be treated successfully with standard chemo- and/or radiotherapy, with 70% of them being alive 10 years after diagnosis. The gold standard treatment for patients that fail first-line treatment is high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autoHSCT).1-4 Patients who fail autoHSCT (or at least two prior lines of therapy) may be treated with brentuximab vedotin (Bv); however, in many patients the disease will progress, with a median overall survival (OS) of approximately 22 months.
Radiolabeled CD45 antibodies have demonstrated clinical promise as targeted conditioning agents prior to bone marrow transplant (BMT) as a better tolerated and potentially more effective alternative to chemotherapy and/or total body irradiation myeloablative conditioning regimens. CD45 is expressed on all immune cells, including hematopoietic stem cells and both precursor and mature lymphoid and myeloid cells, making it an ideal antigen for directing targeted radiation for conditioning. It is also highly expressed on most hematological cancers, offering the potential for a substantial anti-tumor effect.
Bone Marrow Transplantation, Published online: 20 January 2020; doi:10.1038/s41409-020-0789-5Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma
Bone Marrow Transplantation, Published online: 25 November 2019; doi:10.1038/s41409-019-0756-1The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
In conclusion, up-front UBMT was superior to up-front CBT in the low-risk group, but the strategies were comparable in the intermediate- and high-risk groups. PMID: 31701480 [PubMed - as supplied by publisher]
Bone Marrow Transplantation, Published online: 25 September 2019; doi:10.1038/s41409-019-0690-2Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia